10-Q: Cullinan Therapeutics Q3 Loss Widens Amid R&D Boost, Pipeline Shifts

Cullinan Therapeutics reported a wider net loss in Q3 2025, driven by increased R&D expenses including a $20 million license fee for velinotamig, while advancing key oncology and immunology programs and discontinuing others.

Summary

• Net loss for the nine months ended September 30, 2025, widened to $169.2 million, compared to $119.9 million for the same period in 2024.
• Research and development expenses increased by $42.0 million to $144.5 million for the nine months ended September 30, 2025, primarily due to a $20.0 million upfront license fee for velinotamig and higher clinical development costs.
• Cash, cash equivalents, and short-term investments totaled $332.6 million as of September 30, 2025, with total available funds (including long-term investments and interest receivable) of $475.5 million.
• Current capital resources are expected to fund operations for at least the next twelve months from the filing date.
• Zipalertinib's pivotal Phase 2b REZILIENT1 trial met its primary endpoint, with Taiho planning a rolling NDA submission by the end of 2025.
• CLN-619 and CLN-617 development programs were discontinued in November 2025 due to emerging clinical data not meeting internal thresholds.
• CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases, is in Phase 1 trials, with initial safety and B cell depletion data expected in the first half of 2026.
• Velinotamig, a BCMAxCD3 bispecific T cell engager, was in-licensed in June 2025, with a Phase 1 trial in China expected to start by the end of 2025.
• CLN-049, a FLT3xCD3 bispecific T cell engager for AML/MDS, showed anti-leukemic activity in Phase 1, with updated results to be presented at the 2025 ASH Annual Meeting.

Sentiment

Score: 4

Explanation: While there are positive clinical advancements for zipalertinib and CLN-049, and a new asset in-licensed, the significant widening of net loss, increased R&D burn, and the discontinuation of two clinical programs (CLN-619 and CLN-617) indicate substantial challenges and pipeline attrition. The enrollment delays for CLN-978 and potential regulatory delays for zipalertinib add to the concerns. The company's reliance on future capital raises and its shift to a 'smaller reporting company' status also contribute to a cautious outlook.

Positives

• Zipalertinib's pivotal Phase 2b REZILIENT1 trial met its primary endpoint of overall response rate in EGFR ex20ins NSCLC patients.
• Taiho plans to initiate a rolling NDA submission for zipalertinib by the end of 2025, following a positive Type B pre-NDA meeting with the FDA.
• Zipalertinib demonstrated clinical activity in patients with uncommon EGFR mutations and intracranial responses in patients with active brain metastases in the REZILIENT2 cohort.
• CLN-049 showed anti-leukemic activity at clinically active target doses in patients with relapsed/refractory AML.
• A composition of matter patent for CLN-978 was issued, extending patent protection until at least 2042.
• The company has $475.5 million in cash, cash equivalents, and investments, expected to fund operations for at least the next twelve months.
• Successful in-licensing of velinotamig, a BCMAxCD3 bispecific T cell engager, expanding the autoimmune pipeline.

Negatives

• Net loss widened to $169.2 million for the nine months ended September 30, 2025, from $119.9 million in the prior year period.
• Research and development expenses significantly increased, partly due to the $20.0 million upfront license fee for velinotamig and higher clinical development costs.
• Interest income decreased by $4.7 million for the nine months ended September 30, 2025, compared to the same period in 2024.
• CLN-619 and CLN-617 development programs were discontinued in November 2025 due to insufficient clinical data, representing pipeline attrition.
• Experienced more screening failures than anticipated in the CLN-978 SLE clinical trial, leading to enrollment delays.
• Net cash provided by financing activities significantly decreased to $0.3 million for the nine months ended September 30, 2025, compared to $264.6 million in the prior year, which included a large private placement.

Risks

• Difficulty in enrolling patients has delayed, and could further delay or prevent, clinical trials and regulatory approval, as seen with CLN-978.
• The company has a history of significant operating losses and negative cash flows, expecting this to continue for the foreseeable future.
• Future viability depends on the success of research and development and the ability to access additional capital.
• The timing or amount of funds required to complete product development is uncertain and costs could exceed expectations.
• Reliance on third parties to conduct clinical trials and manufacture drug substance/product.
• Competition from companies marketing or developing similar therapies.
• Potential delays in NDA acceptance and review for zipalertinib if the U.S. government shutdown continues, or due to a backlog.
• As a smaller reporting company effective December 31, 2025, reduced reporting requirements could make common stock less attractive to investors, potentially leading to a less active trading market and more volatile stock price.
• The maximum potential amount of future payments under indemnification agreements is, in certain cases, unlimited.

Future Outlook

The company expects to continue generating operating losses for the foreseeable future as it advances its pipeline. Key milestones include Taiho's planned rolling NDA submission for zipalertinib by the end of 2025, initiation of a Phase 1 trial for velinotamig in China by year-end 2025, and expected completion of enrollment for zipalertinib's Phase 3 REZILIENT3 trial in the first half of 2026. Initial safety and B cell depletion data for CLN-978 in SLE and RA are anticipated in the first half of 2026. The company's current capital is projected to fund operations for at least the next twelve months.

Management Comments

• "Our strategy is to identify high-impact targets, which we define as those that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both autoimmune diseases and cancer, and then select what we believe is the optimal therapeutic modality for those targets."
• "We source innovation both internally and externally, focusing on product candidates with novel technology or differentiated mechanisms."
• "We expect that our cash, cash equivalents, and short-term investments of $332.6 million, and long-term investments and interest receivable of $142.9 million as of September 30, 2025, will be sufficient to fund its operating expenses and capital expenditure requirements through the next twelve months from the date of issuance of these consolidated financial statements."
• "We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law."

Industry Context

Cullinan Therapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on immunology and oncology. The company's strategy of identifying high-impact targets and selecting optimal therapeutic modalities aligns with broader industry trends towards precision medicine and targeted therapies. The discontinuation of CLN-619 and CLN-617 reflects the high attrition rate inherent in drug development, while the in-licensing of velinotamig and the advancement of zipalertinib, CLN-978, and CLN-049 demonstrate active pipeline management and strategic focus on promising assets. The collaboration with Taiho for zipalertinib leverages external expertise and resources, a common strategy in the industry to de-risk and accelerate development. The shift to a "smaller reporting company" status highlights the challenges faced by many emerging biotech firms in maintaining market capitalization and revenue thresholds.

Comparison to Industry Standards

• The discontinuation of CLN-619 and CLN-617 due to not meeting internal thresholds for advancement is a common occurrence in the biopharmaceutical industry, where a high percentage of drug candidates fail in clinical trials. This reflects a disciplined approach to pipeline management, similar to how larger pharmaceutical companies prune their portfolios.
• The co-development agreement with Taiho for zipalertinib, including shared development costs and future profits, is a standard collaboration model in the industry, allowing companies to share risks and leverage complementary expertise for global development and commercialization.
• The upfront license fee of $20.0 million for velinotamig, with potential milestone payments up to $692.0 million and tiered royalties, is typical for in-licensing early-stage assets in the biotech sector, reflecting the potential value of novel mechanisms like BCMAxCD3 bispecific T cell engagers.
• The company's cash runway of at least 12 months is a common benchmark for biotech companies, indicating a need for ongoing capital management or future financing, especially given the significant R&D burn rate.

Corporate Governance

Legal Proceedings

• Not currently a party to, or aware of, any material legal proceedings.

Related Party Transactions

• Cullinan has a co-development agreement with an affiliate of Taiho Pharmaceutical Co., Ltd. for zipalertinib, sharing development costs and future pre-tax profits from potential U.S. sales equally.
• Cullinan's development subsidiaries (CLN-619, CLN-049, CLN-617) are party to royalty transfer agreements with two charitable foundations, entitling them to a low single-digit royalty percentage of global net sales.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings; impact from pipeline successes (zipalertinib NDA, CLN-978/CLN-049 data) or failures (CLN-619/CLN-617 discontinuation); potential volatility due to smaller reporting company status.
• Employees: Continued R&D efforts and potential commercialization activities may lead to hiring additional personnel; discontinuation of programs may impact specific teams.
• Customers (Patients): Potential for new therapies for autoimmune diseases and cancer (zipalertinib, velinotamig, CLN-978, CLN-049); discontinuation of programs means certain potential treatments will not advance.
• Creditors/Suppliers: Ongoing operational losses and reliance on future funding may pose risks, though current liquidity is stated as sufficient for 12 months.
• Partners (Taiho, Genrix): Continued collaboration on zipalertinib and velinotamig, with shared risks and potential rewards.

Next Steps

• Taiho plans to initiate a rolling submission of a new drug application (NDA) for zipalertinib in relapsed EGFR ex20ins NSCLC by the end of 2025.
• Chongqing Genrix Biopharmaceutical Co., Ltd. (Genrix) plans to initiate a Phase 1 clinical trial for velinotamig in China by the end of 2025.
• Cullinan Therapeutics will conduct all further global development of velinotamig in autoimmune diseases following the completion of Genrix's Phase 1 trial.
• Initial safety and B cell depletion data for CLN-978 in SLE and RA are planned to be shared in the first half of 2026.
• Taiho expects to complete enrollment of the global Phase 3 REZILIENT3 clinical trial for zipalertinib in the first half of 2026.
• Updated results for CLN-049 will be shared in an oral presentation at the 2025 ASH Annual Meeting in December 2025.
• The company will continue to evaluate and advance its preclinical programs.

Key Dates

Recommendation

The company presents a mixed bag of developments. On one hand, the zipalertinib program is progressing well with a planned NDA submission, and CLN-049 shows promise. The in-licensing of velinotamig also adds a new asset to the pipeline. These positive clinical advancements could drive future value. However, the significant widening of the net loss, increased R&D expenses, and the discontinuation of two clinical programs (CLN-619 and CLN-617) highlight the inherent risks and high attrition rate in biotech. Enrollment delays for CLN-978 and potential regulatory delays for zipalertinib add uncertainty. The company's reliance on future capital raises, despite current liquidity, and the transition to a "smaller reporting company" status suggest potential headwinds. Given the balance of promising pipeline assets against substantial financial losses and program discontinuations, a "hold" recommendation is appropriate for investors to monitor the progress of key clinical trials and regulatory submissions, as well as the company's financial management and capital raising efforts.

Keywords

Cullinan Therapeutics, biopharmaceutical, clinical-stage, autoimmune diseases, cancer, oncology, immunology, zipalertinib, EGFR ex20ins NSCLC, velinotamig, BCMAxCD3, CLN-978, CD19xCD3, CLN-049, AML, MDS, drug development, clinical trials, NDA submission, SEC filing, 10-Q, biotech, pharmaceuticals